A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcinoma: The IMPACT study.

Marina Tschaika,Hans-Joachim Schmoll,Jorge Riera-Knorrenschild,H. Kröning,Frank Mayer,Ekaterina Weith,Matthias Schroff,Maxim Krikov,Manuel Schmidt,Burghardt Wittig

A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcinoma: The IMPACT study.

2017

Marina Tschaika
Hans-Joachim Schmoll
Jorge Riera-Knorrenschild
H. Kröning
Frank Mayer
Ekaterina Weith
Matthias Schroff
Maxim Krikov
Manuel Schmidt
Burghardt Wittig

e14152 Background: Based on promising data from a phase 1 study of MGN1703 in patients with metastatic solid tumors including those with CRC, a phase 2-3 study was initiated in patients with advanc...

Keywords:

Medicine
Colorectal cancer
Oncology
Internal medicine
Pathology
impact study
in patient
clinical study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations